Cited by 590interferon and immune responsesCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

Open access

Xia, Tianli, Konno, Hiroyasu, Ahn, Jeonghyun, Barber, Glen N.·2016·Cell Reports

DOI 10.1016/j.celrep.2015.12.029PMC PMC4845097

Open this paper in CoChat — free account Open PDF

Abstract

Stimulator of interferon genes (STING) has been shown to be critical for controlling antiviral responses as well as anti-tumor adaptive immunity, but little is known regarding its regulation in human tumors. Here, we report that STING signaling is recurrently suppressed in a wide variety of cancers, including colorectal carcinoma. Loss of STING signaling impeded DNA damage responses accountable for generating key cytokines that facilitate tissue repair and anti-tumor T cell priming, such as type I interferons (IFNs). Correspondingly, defective STING function was also highly predictive of effectual DNA-virus-mediated oncolytic activity. Thus, impaired STING responses may enable damaged cells to evade host immunosurveillance processes, although they provide a critical prognostic measurement that could help predict the outcome of effective oncoviral therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2015.12.029

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Self-citation
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,925
Cancer treatment and survivorship statistics, 2014
Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 5×
“Tumors with defective STING-Signaling are sensitive to viral Oncolysis We have previously shown that loss of STING signaling in vitro or in vivo renders cells or mice, respectively, extremely sensitive to Herpes simplex virus (HSV) infection (Ishikawa and Barber, 2008; Ishikawa et al., 2009).”
BackgroundMethodInfluentialSelf-citation
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 101–200 of 590

Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy
Yum, S., Li, M., Frankel, A. E., & Chen, Z. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055636 · Cited by 109
Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice
Martin, G. R., Blomquist, C. M., Henare, K. L., & Jirik, F. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-50656-5 · Cited by 109
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
Matveeva, O. V., & Chumakov, P. M. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2008 · Cited by 113
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
Signaling Through Nucleic Acid Sensors and Their Roles in Inflammatory Diseases
Okude, H., Ori, D., & Kawai, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.625833 · Cited by 104
A Nuclear Export Signal Is Required for cGAS to Sense Cytosolic DNA
Sun, H., Huang, Y., Mei, S., Xu, F., Liu, X., Zhao, F., Yin, L., Zhang, D., Wei, L., Wu, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108586 · Cited by 105
cGAS-STING signaling in cancer immunity and immunotherapy
Du, H., Xu, T., & Cui, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110972 · Cited by 106
STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability
Rañoa, D. R. E., Widau, R. C., Mallon, S., Parekh, A. D., Nicolae, C. M., Huang, X., Bolt, M. J., Arina, A., Parry, R., Kron, S. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1972 · Cited by 103
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition
Low, J., Chandramohan, V., Bowie, M. L., Brown, M. C., Waitkus, M. S., Briley, A., Stevenson, K., Fuller, R., Reitman, Z. J., Muscat, A. M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.009 · Cited by 101
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment
Elion, D. L., & Cook, R. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25626 · Cited by 99
cGAS-STING pathway in oncogenesis and cancer therapeutics
Hoong, B. Y. D., Gan, Y., Liu, H., & Chen, E. S. (2020) · Oncotarget · doi:10.18632/oncotarget.27673 · Cited by 106
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Zhang, B., & Cheng, P. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01275-6 · Cited by 102
IRF3 activates RB to authorize cGAS-STING–induced senescence and mitigate liver fibrosis
Wu, Q., Leng, X., Zhang, Q., Zhu, Y., Zhou, R., Liu, Y., Chen, M., Zhang, D., Liu, S., Chen, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj2102 · Cited by 101
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95
Self-citation
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 94
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Cetinbas, N. M., Monnell, T. E., Soomer-James, J., Shaw, P., Lancaster, K. L., Catcott, K. C., Dolan, M., Mosher, R. E., Routhier, C. A., Chin, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49932-4 · Cited by 100
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94
Self-citation
Regulation and Consequences of cGAS Activation by Self-DNA
Zierhut, C., & Funabiki, H. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.05.006 · Cited by 91
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
McWhirter, S. M., & Jefferies, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.004 · Cited by 91
STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy
Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M. F., Motwani, J., Gallagher, S. J., Shklovskaya, E., Tiffen, J. C., Eccles, M. R., et al. (2018) · iScience · doi:10.1016/j.isci.2018.05.021 · Cited by 92
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 93
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer
Lawler, M., Alsina, D., Adams, R., Anderson, A. S., Brown, G. M., Fearnhead, N. S., Fenwick, S. W., Halloran, S. P., Hochhauser, D., Hull, M. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315333 · Cited by 91
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 91
STING signaling is a potential immunotherapeutic target in colorectal cancer
Chon, H. J., Kim, H., Noh, J. H., Yang, H., Lee, W. S., Kong, S. J., Lee, S., Lee, Y. S., Kim, W. R., Kim, J. H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.32806 · Cited by 83
cGAS restricts colon cancer development by protecting intestinal barrier integrity
Hu, S., Fang, Y., Chen, X., Cheng, T., Zhao, M., Du, M., Li, T., Li, M., Zeng, Z., Wei, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105747118 · Cited by 84
STING directly recruits WIPI2 for autophagosome formation during STING‐induced autophagy
Wan, W., Qian, C., Wang, Q., Li, J., Zhang, H., Wang, L., Pu, M., Huang, Y., He, Z., Zhou, T., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022112387 · Cited by 84
Virulent Poxviruses Inhibit DNA Sensing by Preventing STING Activation
Georgana, I., Sumner, R. P., Towers, G. J., & de Motes, C. M. (2018) · Journal of Virology · doi:10.1128/jvi.02145-17 · Cited by 85
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors
Ying, X., Chen, Q., Yang, Y., Wu, Z., Zeng, W., Miao, C., Huang, Q., & Ai, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02186-6 · Cited by 87
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Pol, J. G., Lévesque, S., Workenhe, S. T., Gujar, S. A., Bœuf, F. L., Clements, D. R., Fahrner, J., Fend, L., Bell, J. C., Mossman, K. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1503032 · Cited by 82
A distinct role of STING in regulating glucose homeostasis through insulin sensitivity and insulin secretion
Qiao, J., Zhang, Z., Ji, S., Liu, T., Zhang, X., Huang, Y., Feng, W., Wang, K., Wang, J., Wang, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101848119 · Cited by 78
Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity
Li, L., Li, Y., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., Zhang, K., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1027-x · Cited by 78
Radiotherapy: An immune response modifier for immuno-oncology
Martino, M. D., Daviaud, C., & Vanpouille‐Box, C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101474 · Cited by 81
DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling
Shen, R., Liu, D., Wang, X., Guo, Z., Sun, H., Song, Y., & Wang, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.828657 · Cited by 77
Role of Type I and II Interferons in Colorectal Cancer and Melanoma
Franco, S. D., Turdo, A., Todaro, M., & Stassi, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00878 · Cited by 76
Diverse Roles of Protein Palmitoylation in Cancer Progression, Immunity, Stemness, and Beyond
Li, M., Zhang, L., & Chen, C.-W. D. (2023) · Cells · doi:10.3390/cells12182209 · Cited by 76
STING Signaling in Cancer Cells: Important or Not?
Sokołowska, O., & Nowis, D. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0481-7 · Cited by 79
Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma
Low, J., Brown, M. C., Reitman, Z. J., Bernstock, J. D., Markert, J. M., Friedman, G. K., Waitkus, M. S., Bowie, M. L., & Ashley, D. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci163452 · Cited by 81
The senescence journey in cancer immunoediting
Zingoni, A., Antonangeli, F., Sozzani, S., Santoni, A., Cippitelli, M., & Soriani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01973-5 · Cited by 77
STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity
Pei, J., Zhang, Y., Luo, Q., Zheng, W., Li, W., Zeng, X. Y., Li, Q., & Quan, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.029 · Cited by 74
Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins
Cigno, I. L., Calati, F., Albertini, S., & Gariglio, M. (2020) · Pathogens · doi:10.3390/pathogens9040292 · Cited by 73
cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
Long, Z., Wang, J., Xu, J., Lei, X., & Liu, Q. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.044 · Cited by 76
cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells
Suter, M. A., Tan, N. Y., Thiam, C. H., Khatoo, M., MacAry, P. A., Angeli, V., Gasser, S., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86644-x · Cited by 72
The Evolution of STING Signaling and Its Involvement in Cancer
Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 72
Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation
Alwithenani, A., Hengswat, P., & Chiocca, E. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.035 · Cited by 71
A novel transcript isoform of STING that sequesters cGAMP and dominantly inhibits innate nucleic acid sensing
Wang, P., Fung, S., Gao, W., Deng, J., Cheng, Y., Chaudhary, V., Yuen, K., Ho, T., Chan, C.-P., Zhang, Y., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky186 · Cited by 70
Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
Luo, K.-W., Li, N., Ye, W., Gao, H., Luo, X., & Cheng, B. (2022) · Molecules · doi:10.3390/molecules27144638 · Cited by 68
Enhancing the efficacy of immunotherapy using radiotherapy
Keam, S., Gill, S., Ebert, M. A., Nowak, A. K., & Cook, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1169 · Cited by 69
STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity
Zhu, Z., Zhou, X., Du, H., Cloer, E. W., Zhang, J., Liu, M., Wang, Y., Tan, X. M., Hepperla, A. J., Simon, J. M., et al. (2022) · Advanced Science · doi:10.1002/advs.202203718 · Cited by 71
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 73
cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response
Bose, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112456 · Cited by 69
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Vargas, T. R., Benoit-Lizon, I., & Apétoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 66
Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
Raulet, D. H., Marcus, A., & Coscoy, L. (2017) · Immunological Reviews · doi:10.1111/imr.12600 · Cited by 66
Mutational game changer: Chromothripsis and its emerging relevance to cancer
Luijten, M., Lee, J. X. T., & Crasta, K. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.06.004 · Cited by 65
Selective reactivation of STING signaling to target Merkel cell carcinoma
Liu, W., Kim, G. B., Krump, N. A., Zhou, Y., Riley, J. L., & You, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919690117 · Cited by 65
STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer
Lu, S., Concha‐Benavente, F., Shayan, G., Srivastava, R. M., Gibson, S. P., Wang, L., Gooding, W. E., & Ferris, R. L. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.01.019 · Cited by 65
Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice
Lai, J., Fu, Y., Tian, S., Huang, S., Luo, X., Lin, L., Zhang, X., Wang, H., Lin, Z., Zhao, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.005 · Cited by 63
Genotoxic stress and viral infection induce transient expression of APOBEC3A and pro-inflammatory genes through two distinct pathways
Oh, S., Bournique, E., Bowen, D., Jalili, P. R., Sanchez, A., Ward, I., Dananberg, A., Manjunath, L., Tran, G. P., Semler, B. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25203-4 · Cited by 63
Targeting STING for cancer immunotherapy: From mechanisms to translation
Huang, R., Ning, Q., Zhao, J., Zhao, X., Zeng, L., Yi, Y., & Tang, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109304 · Cited by 64
cGAS/STING signalling pathway in senescence and oncogenesis
Yu, L., & Liu, P. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.007 · Cited by 67
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille‐Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 63
HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport
Khan, H., Sumner, R. P., Rasaiyaah, J., Tan, C. P., Rodriguez-Plata, M. T., van Tulleken, C., Fink, D., Zuliani‐Alvarez, L., Thorne, L., Stirling, D. R., et al. (2020) · eLife · doi:10.7554/elife.60821 · Cited by 64
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
Shaver, K. A., Croom-Perez, T. J., & Copik, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679117 · Cited by 68
An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy
Cao, Y., Ding, S., Hu, Y., Zeng, L., Zhou, J., Lin, L., Zhang, X., Ma, Q., Cai, R., Zhang, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c09293 · Cited by 63
Opportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 73
HIV-2/SIV Vpx targets a novel functional domain of STING to selectively inhibit cGAS–STING-mediated NF-κB signalling
Su, J., Rui, Y., Lou, M., Yin, L., Xiong, H., Zhou, Z., Shen, S., Chen, T., Zhang, Z., Zhao, N., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0585-4 · Cited by 62
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
Cigno, I. L., Calati, F., Girone, C., Catozzo, M., & Gariglio, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29685 · Cited by 65
Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma
Bu, Y., Liu, F., Jia, Q., & Yu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165681 · Cited by 62
STING signaling in tumorigenesis and cancer therapy: A friend or foe?
He, L., Xiao, X., Yang, X., Zhang, Z., Wu, L., & Liu, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.026 · Cited by 62
SAMHD1 and the innate immune response to cytosolic DNA during DNA replication
Coquel, F., Neumayer, C., Lin, Y., & Pasero, P. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.09.017 · Cited by 62
Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer
Kaneta, A., Nakajima, S., Okayama, H., Matsumoto, T., Saito, K., Kikuchi, T., Endo, E., Ito, M., Mimura, K., Kanke, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03200-w · Cited by 59
cGAS–STING signalling in cancer: striking a balance with chromosomal instability
Beernaert, B., & Parkes, E. E. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220838 · Cited by 60
Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy
Vornholz, L., Isay, S. E., Kurgyis, Z., Strobl, D. C., Loll, P., Mosa, M. H., Luecken, M. D., Sterr, M., Lickert, H., Winter, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.add8564 · Cited by 60
The role of cGAS in innate immunity and beyond
Ablasser, A., & Gulen, M. F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1423-2 · Cited by 57
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
Staniszewska, A. D., Armenia, J., King, M. A., Michaloglou, C., Reddy, A., Singh, M., Martin, M. S., Prickett, L. B., Wilson, Z., Proia, T. A., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083755 · Cited by 59
cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer
Kabashima, A., Matsuo, Y., Ito, S., Akiyama, Y., Ishii, T., Shimada, S., Masamune, A., Tanabe, M., & Tanaka, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14297-5 · Cited by 55
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
Yin, J., Markert, J. M., & Leavenworth, J. W. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00136 · Cited by 55
Bioactive modulators targeting STING adaptor in cGAS-STING pathway
Feng, X., Liu, D., Li, Z., & Bian, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.007 · Cited by 53
The TLR3/IRF1/Type III IFN Axis Facilitates Antiviral Responses against Enterovirus Infections in the Intestine
Su, R., Shereen, M. A., Zeng, X., Liang, Y., Li, W., Ruan, Z., Li, Y., Liu, W., Liu, Y., Wu, K., et al. (2020) · mBio · doi:10.1128/mbio.02540-20 · Cited by 52
cGAS–STING signaling pathway in gastrointestinal inflammatory disease and cancers
Ke, X., Hu, T., & Jiang, M. (2021) · The FASEB Journal · doi:10.1096/fj.202101199r · Cited by 52
The interplay between autophagy and cGAS-STING signaling and its implications for cancer
Schmid, M., Fischer, P., Engl, M., Widder, J., Gruber, S., & Slade, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356369 · Cited by 61
Autoimmune disease: a view of epigenetics and therapeutic targeting
Mu, S., Wang, W., Liu, Q., Ke, N., Li, H., Sun, F., Zhang, J., & Zhu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482728 · Cited by 57
cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity
Pépin, G., & Gantier, M. P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5987-2_8 · Cited by 53
Regulation and inhibition of the DNA sensor cGAS
Hertzog, J., & Rehwinkel, J. (2020) · EMBO Reports · doi:10.15252/embr.202051345 · Cited by 52
cGAS-STING signaling pathway in intestinal homeostasis and diseases
Yang, Y., Wang, L., Peugnet-González, I., Parada‐Venegas, D., Dijkstra, G. D. H., & Faber, K. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239142 · Cited by 51
NLRX1 regulates TNF-α-induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells
Singh, K., Roy, M., Prajapati, P., Lipatova, A. V., Sripada, L., Gohel, D., Singh, A., Mane, M., Godbole, M. M., Chumakov, P. M., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.02.018 · Cited by 56
Innate immune response orchestrates phosphoribosyl pyrophosphate synthetases to support DNA repair
Liu, R. R., Li, J., Shao, J., Lee, J.-H., Qiu, X., Xiao, Y., Zhang, B., Hao, Y., Li, M., & Chen, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.009 · Cited by 49
Tumor-intrinsic determinants of immunogenic cell death modalities
Workenhe, S. T., Pol, J. G., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1893466 · Cited by 52
cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity
Mekers, V. E., Kho, V. M., Ansems, M., & Adema, G. J. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.07.014 · Cited by 47
Modification of BRCA1-associated breast cancer risk by HMMR overexpression
Mateo, F., He, Z., Mei, L., Ponce, G. R. D. G., Herranz, C., García, N., Lorentzian, A. C., Baiges, A., Blommaert, E., Gómez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29335-z · Cited by 51
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
McPherson, A., Vázquez-Garćıa, I., Myers, M. A., Al-Rawi, D. H., Zatzman, M., Weiner, A. C., Freeman, S. S., Mohibullah, N., Satas, G., Williams, M. J., et al. (2025) · Nature · doi:10.1038/s41586-025-09240-3 · Cited by 66
Human Cancer Cells Sense Cytosolic Nucleic Acids Through the RIG-I–MAVS Pathway and cGAS–STING Pathway
Qiao, Y., Zhu, S., Deng, S., Zou, S.-S., Gao, B., Zang, G., Wu, J., Jiang, Y., Liu, Y.-J., & Chen, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606001 · Cited by 47
Regulation and function of the cGAS-MITA/STING axis in health and disease
Zhang, Z.-D., & Zhong, B. (2022) · Cell Insight · doi:10.1016/j.cellin.2021.100001 · Cited by 44
Sulfonated Perylene as Three‐in‐One STING Agonist for Cancer Chemo‐Immunotherapy
Zhao, X., Zheng, R., Zhang, B., Zhao, Y., Xue, W., Fang, Y., Huang, Y., & Yin, M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318799 · Cited by 44
Activation of cGAS-dependent antiviral responses by DNA intercalating agents
Pépin, G., Nejad, C., Thomas, B. J., Ferrand, J., McArthur, K., Bardin, P. G., Williams, B. R. G., & Gantier, M. P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw878 · Cited by 50
The triggers of the cGAS-STING pathway and the connection with inflammatory and autoimmune diseases
Zhou, R., Xie, X., Li, X., Qin, Z., Wei, C., Liu, J., & Luo, Y. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.104094 · Cited by 46
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 45
Ligands stimulating antitumour immunity as the next G-quadruplex challenge
Miglietta, G., Marinello, J., Russo, M., & Capranico, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01649-y · Cited by 44
“As STING gene promoter is often methylated in tumours, demethylating agents may increase STING expression and innate immune response upon induction of DNA damage by anticancer agents [132].”
Background

Authors: Xia, T., Konno, H., Ahn, J., & Barber, G. N.
Affiliations: University of Miami (US)
Corresponding author: Barber, Glen N.
ORCID: Konno, Hiroyasu
Ahn, Jeonghyun
Barber, Glen N.
Venue: Cell Reports
Publisher: Elsevier BV
Published: 2016-01
Volume: 14
Issue: 2
Pages: 282-297
ISSN: 2211-1247 (ISSN-L)
DOI: 10.1016/j.celrep.2015.12.029
PMC: PMC4845097
OpenAlex: W2220279767
Cited by: 589
References: 50
Citations by year: 2026: 46 · 2025: 61 · 2024: 70 · 2023: 66 · 2022: 77 · 2021: 76 · 2020: 51 · 2019: 57 · 2018: 44 · 2017: 28 · 2016: 13
FWCI: 13.97
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Cell Reports (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Sylvester Comprehensive Cancer Center, University of Miami Health Systems
National Cancer Institute (R01CA194404)
National Institute of Allergy and Infectious Diseases (R01AI079336)
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: STING signaling, colorectal cancer, DNA damage response, type I interferon, tumor surveillance, DNA viruses, carcinogenesis, prognostic factors, tissue repair
MeSH terms: Animals, DNA Damage, Humans, Transfection, Colorectal Neoplasms, Signal Transduction, Mice, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks